When a child is diagnosed with cancer, their family is presented with treatment options – often a combination of surgery, radiation and chemotherapy. Radiation and chemotherapy have been used to treat kids’ cancers for more than 50 years and often come with long-term late effects including secondary cancers, heart damage and cognitive issues. Often a child’s best chance at survival is a clinical trial which offers them the newest treatment options available.
In recognition of Childhood Cancer Awareness Month, the St. Baldrick’s Foundation will highlight the critical need to fund lifesaving research and share stories of kids affected by cancer – like Micah, who is alive today because there was a clinical trial available.
To view the multimedia release go to:
https://www.multivu.com/players/English/8284352-st-baldricks-foundation-conquer-childhood-cancers/
St. Jude Children’s Research Hospital® officials and guests today marked the opening of the St. Jude Red Frog Events Proton Therapy Center, the first proton therapy center in the world dedicated solely to children with cancer.
Patients are now being treated at the center using precisely delivered, high-energy particles called protons to kill or shrink tumors while minimizing damage to healthy tissue and organs. For patients with brain tumors and certain other cancers, research suggests proton beam therapy may be more effective than conventional radiation at preventing the growth and spread of tumors while reducing the risk of treatment-related side effects.
To view the multimedia release go to:
http://www.multivu.com/players/English/7713451-st-jude-proton-therapy-opening/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
House of Napius is India's first line of radiation safe maternity wear using path breaking NESA technology (Non-Ionizing Electromagnetic Shielding Alternatives.
Most expectant mothers understand that carrying a child means taking extra safety measures to protect the growing life. Mothers-to-be are aware that they need to avoid certain chemicals, foods, and some beverages. Our line of radiation safe maternity wear provides an additional safeguard by shielding against radiation from cell phones, wireless routers, laptop and computers. House of Napius offers a wide range of revolutionary, radiation safe Maternity wear for the first time in India.
With a lack of choice and growing radiation concerns Founder Director, Nehal Mehta says: “Today we cannot live a gadget or appliance free lifestyle. At House of Napius, we have created a solution to block the radiation from these gadgets which are used on a daily basis such as cellphones, microwaves, laptops, scanners and ipads. We are launching our first product category of maternity wear and will be expanding into other categories such a kidswear, womenswear and menswear in the future.”
When it comes to dressing during pregnancy, comfort and style are key factors/aspects. The new range of maternity wear by House of Napius includes office wear, day wear, resort, night wear and cocktail dresses. Each garment is designed to not only protect the child, but provide unparalleled comfort and ease of use for the pregnant mother. House of Napius maternity wear is available in a multitude of colours’ and patterns and will keep your child protected all through those precious nine months.
To view the Multimedia release go to:
http://www.multivu.com/players/English/7595451-house-napius-maternity-wear-india/
It’s back to school and more youth than ever are involved in some type of sporting activity. That’s why approximately three million youth are seen in hospital emergency rooms for sports-related injuries and another five million are seen by their primary care physician or a sports medicine clinic for injuries. Many of those injuries may result in your child having to have a CT scan.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7272451-lurie-children-s-hospital-of-chicago-ct-scan-radiation-dose/
Until recently, cancer patients looking for the most precise form of proton radiation therapy – “pencil-beam scanning” – had to narrow their search to about a half dozen centers in the United States that offer this treatment on a limited basis.
Today’s opening of the Scripps Proton Therapy Center in San Diego, Calif., marks the first time that a proton center in the United States is treating patients exclusively with this ultra-accurate technology, in every treatment room.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65691-scripps-proton-therapy-center-san-diego-precise-cancer-care
Nucletron, an Elekta company, and the world leader in brachytherapy, has launched Esteya®, a new approach for treating patients with skin cancer.
Over the last 30 years, more people were diagnosed with skin cancer worldwide than all other cancers combined, making it the most common type of cancer1. This represents a challenge for health care providers in the years to come. With a cure rate of more than 95 percent2, electronic brachytherapy offers a refined treatment modality with excellent cosmesis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62823-elekta-nucletron-esteya-electronic-brachytherapy-treating-skin-cancer
During a live global event, Elekta announced the launch of Versa HD™, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers. Featuring high precision beam shaping and tumor targeting, Versa HD also unveils new capabilities designed to maximize health care system resources and deliver highly sophisticated therapies without compromising treatment times.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60246-elekta-sets-new-benchmark-for-cancer-treatment-launch-of-versa-hd-system
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
When Kayla Dehnert tells friends and family in Northern California about life as a St. Jude Children’s Research Hospital patient, she pulls out a string of beads taller than she is.
Kayla, 8, of Novato, Calif., is one of hundreds of St. Jude patients who have participated in the hospital’s Legacy Bead program since its launch in 2009. The program offers patients and their families a tangible way to illustrate their journeys using 55 glass beads as unique as the children who collect them. Patients receive vivid green cylindrical beads for blood transfusions; sapphire round beads for lumbar punctures; tear-drop beads in assorted colors for homesickness; and blue, triangle-shaped beads for clinic visits. Other beads mark triumphs such as the completion of radiation or chemotherapy or challenges ranging from cancer’s return to the death of a friend.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58137-st-jude-legacy-bead-program-treatment-milestones-for-children
